Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NT-1044
- Development stage
- Preclinical
- Lead developer
- Pano Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NT-1044 is a novel small molecule biguanide and AMPK activator developed by NovaTarg Therapeutics. It was designed to improve upon the anti-tumorigenic properties of metformin by exhibiting higher affinity for organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3), which facilitate cellular entry. In preclinical studies for endometrial cancer, NT-1044 has demonstrated the ability to inhibit cell proliferation, induce G1 cell cycle arrest and apoptosis, and suppress the mTOR pathway (evidenced by decreased S6 phosphorylation). It has also shown efficacy in reducing tumor weight in mouse models of endometrioid endometrial cancer, suggesting potential utility in treating cancers associated with obesity and diabetes.
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)mTOR (Mammalian target of rapamycin kinase)OCT1 (Organic cation transporter 1)OCT2 (Organic cation transporter 2)OCT3 (Organic cation transporter 3)
Beyond the preview
Go deeper on NT-1044.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NT-1044.